NIH Observational Study Evaluates PET/CT Imaging Agent 64Cu-DOTA-ECL1i for Abdominal Aortic Aneurysm Inflammation
Summary
This ClinicalTrials.gov registration documents NCT07548099, an observational study sponsored by the NIH investigating the molecular imaging agent 64Cu-DOTA-ECL1i in combination with PET/CT scanning to visualize inflammation in abdominal aortic aneurysms. The study aims to understand how aneurysm inflammation develops over time and what factors influence it, using a novel radiopharmaceutical designed to target vessel wall inflammation. Enrollment details, eligibility criteria, and specific study locations would be available in the complete ClinicalTrials.gov record.
“This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov registration documents a new observational study (NCT07548099) registered with the NIH on April 23, 2026. The study will use 64Cu-DOTA-ECL1i, a novel PET/CT imaging agent, to generate images of inflammation in the aorta of patients with abdominal aortic aneurysm. The aim is to understand how inflammation correlates with aneurysm growth and to assess the consistency of imaging results over time.
For patients with abdominal aortic aneurysm and healthcare providers involved in vascular imaging: this study represents an exploratory investigation into a potential new molecular imaging approach. The study is observational in design, meaning 64Cu-DOTA-ECL1i is administered for imaging purposes only and does not constitute a therapeutic intervention. Clinical investigators and institutional review boards should note that this study is registered and publicly available on ClinicalTrials.gov.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)
Observational NCT07548099 Kind: OBSERVATIONAL Apr 23, 2026
Abstract
This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET/CT (Positron Emission Tomography/Computed Tomography).
The aim is to collect data using a new imaging drug called 64Cu-DOTA-ECL1i that may be able to create images of inflammation in the aorta, which is thought to be important in how aneurysms grow and develop and to understand how consistent these scans are across time and what might affect the inflammation.
Conditions: Abdominal Aortic Aneurysm
Interventions: 64Cu-DOTA-ECL1i
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.